GAS6 and breast cancer: These different results observed in these studies may be explained by the differences in the tumor models used (breast cancer vs. pancreatic cancer; xenograft vs. syngeneic models) and the differences in the therapies used (inhibition of AXL receptor vs. inhibition of Gas6 ligand which binds all TAM receptors).